1 recruiting, 1 unknown. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 1, Unknown 1 |
Follow Neurological Disorder: new trials by email Literature Review of Neurological Disorder trials Research Report on Neurological Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury Ceftriaxone 2g diluted in >200ml 0.9%sodium chloride, Placebo comparator - no ceftriaxone - All-cause Mortality, Quality of Life | Phase 3 | Recruiting | The George Institute | 3300 | 2025-10-30 | 2026-08-28 |
| Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension - Autism Spectrum Disorder, Sleep Disorder | Phase 3 | Unknown | Vanda Pharmaceuticals | 100 | 2021-07-28 | 2024-03-21 |
Nervous System Diseases (2) · Autism Spectrum Disorder (1) · Brain Injuries (1) · Intellectual Disability (1) · Parasomnias (1) · Respiratory Aspiration (1) · Sleep Wake Disorders (1)
Mental Disorders (2) · Neurodevelopmental Disorders (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Child Development Disorders, Pervasive (1) · Craniocerebral Trauma (1) · Neurobehavioral Manifestations (1) · Pathologic Processes (1) · Respiration Disorders (1) · Respiratory Tract Diseases (1) · Trauma, Nervous System (1) · Wounds and Injuries (1)
Ceftriaxone (1) · Sodium Chloride (1)
The George Institute (1) · Vanda Pharmaceuticals (1)
Australia (1) · Canada (1) · New Zealand (1) · United States (1)
Andrew Udy, Prof (1) · Anthony Delaney, Prof (1) · Edward Litton, Prof (1) · Paul Young, Prof (1)